DAPA-CKD Biomarker Analysis: Dapagliflozin Lowered KIM-1 and MCP-1, and Early Changes Tracked With Outcomes

In 2,795 DAPA-CKD participants, higher baseline TNFR-1, TNFR-2, KIM-1 and urinary MCP-1 predicted worse kidney and cardiovascular outcomes. At 1 year, dapagliflozin lowered plasma KIM-1 by 16.6% and urinary MCP-1/Cr by 17.8% versus placebo but did not change TNFR-1. This is an exploratory post hoc b

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.